Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OMD Appoints RGi for the Industrial Design of Breath Ketone Analysis Platform

Published: Tuesday, March 25, 2014
Last Updated: Tuesday, March 25, 2014
Bookmark and Share
New system aims to reduce the incidence of Diabetic KetoAcidosis.

Oxford Medical Diagnostics (OMD) has contracted Renfrew Group International (RGi) for the industrial design of a portable breath analysis platform based upon OMD’s prototype device.

The collaboration will combine OMD’s scientific research expertise with RGi’s design capabilities to further develop an accurate, low-cost, portable and non-invasive breath analysis platform to identify and monitor certain metabolic and infectious diseases by detecting and measuring VOCs in breath.

The current device is designed for use in Type 1 diabetes, as an aid to diabetes management and to help prevent the onset of Diabetic KetoAcidosis (DKA).

In recent months the prototype system was successfully used in its first clinical evaluation, successfully measuring breath acetone from over 100 samples.

OMD’s platform is based on the Company’s main proprietary technology, Cavity Enhanced Absorption Spectroscopy (CEAS), which was developed at the University of Oxford.

The current prototype device is capable of measuring acetone in breath samples at sub-parts-per-million levels, which is in excess of the sensitivity required to detect acetone levels of patients with Type 1 diabetes.

OMD has been awarded SBRI funding and two TSB grants to support this work. The Company is currently performing the next phase of clinical trials in collaboration with an expert team at Addenbrookes Hospital in Cambridge under the direction of Dr Mark Evans.

OMD's CEO, Dr Ian Campbell, stated: "Appointing RGi is a significant step forward for OMD. Given the robust performance of the prototype in the clinical evaluation we are now in a position to move forward with a design for manufacture.”

Bruce Renfrew, Managing Director of RGi commented: “RGi is delighted to be working with OMD to industrialize this innovative, non-invasive diagnostic platform.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oxford Medical Diagnostics and Michell Instruments Launch Gas Analysis Partnership
OMD and MI will jointly develop new industrial gas detection and measurement devices for a number of industrial applications.
Wednesday, August 17, 2011
OMD Obtains Close to GBP One Million in New Financing Round
Current investors and shareholders provide funding for further development of breath analysis device for diabetes.
Friday, June 03, 2011
OMD and V&F Join Forces in the Field of Mass Spectrometry
Oxford Medical Diagnostics will offer V&F mass spectrometry analyzers and batch sample analysis service in the UK and Ireland.
Tuesday, March 08, 2011
Graham Richards joins Science Advisory Panel at Oxford Medical Diagnostics
Entrepreneurial Oxford professor will also bring his experience of successful technology start-ups to breath analysis specialists.
Monday, January 24, 2011
Scientific News
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Bioreactors Ready for the Big Time
Bioreactors are passive filtration systems that can reduce nitrate losses from farm fields.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!